Steven Neus
Family Medicine · Foster, KYNPI 1801895396
Payments from drug & device makers
Across 182 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$385
- AbbVie$296
- Novo Nordisk$227
- Astellas Pharma US Inc$205
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$194
- GSK$194
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,11596%
- Education$1154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,229 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 371 | $155,436 |
| OzempicSemaglutide | 93 | $91,693 |
| XareltoRivaroxaban | 106 | $84,473 |
| OtezlaApremilast | 16 | $77,326 |
| JardianceEmpagliflozin | 126 | $74,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $68,762 |
| FarxigaDapagliflozin Propanediol | 82 | $63,557 |
| MounjaroTirzepatide | 43 | $45,686 |
| XifaxanRifaximin | 13 | $41,471 |
| TrulicityDulaglutide | 26 | $30,125 |
| VraylarCariprazine Hcl | 20 | $28,323 |
| NamzaricMemantine Hcl/Donepezil Hcl | 48 | $21,679 |
| JanuviaSitagliptin Phosphate | 14 | $20,537 |
| EntrestoSacubitril/Valsartan | 32 | $19,072 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $18,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $155,436371 claims |
| Novo NordiskOzempic | $227 | $91,69393 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $194 | $87,072128 claims |
| Johnson & JohnsonXarelto | $29 | $84,473106 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $12 | $79,721138 claims |
| AmgenOtezla | $95 | $77,32616 claims |
| Lilly USA, LLCMounjaro, Trulicity | $66 | $75,81169 claims |
| AstraZenecaFarxiga, Brilinta | $110 | $71,83293 claims |
| AbbVieVraylar, Namzaric, Linzess | $296 | $58,42080 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $194 | $41,47113 claims |
| MerckJanuvia | $15 | $20,53714 claims |
| NovartisEntresto | $45 | $19,07232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Foster
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.